IC
RCKTW icon

Ikarian Capital’s Rocket Pharmaceuticals Warrant RCKTW Stock Holding History

Ikarian Capital’s Portfolio RCKTW Stock Details RCKTW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-367,112
Closed -$60K – 153
2023
Q1 		$60K Buy
+367,112
New +$70.8K 0.01% 114

Other funds holding RCKTW

BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
FBCM
Fort Baker Capital Management Larkspur, California $1.37B AUM 26.91% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

Ikarian Capital's RCKTW Position: Q2 2023 in Review

Ikarian Capital sold out of Rocket Pharmaceuticals Warrant (RCKTW) in Q2 2023, closing a stake of 367,112 shares — an estimated $60K sold.

Ikarian Capital first reported a position in RCKTW in Q1 2023 and held it in 1 quarter. The position peaked at $60K in Q1 2023. 16 funds tracked by Wall St. Rank hold RCKTW as of Q2 2023.

  • Ikarian Capital reported no remaining Rocket Pharmaceuticals Warrant position as of Q2 2023 after selling out during the quarter.
  • Ikarian Capital sold 367,112 Rocket Pharmaceuticals Warrant shares in Q2 2023, an estimated $60K.
  • Ikarian Capital first reported a position in Rocket Pharmaceuticals Warrant in Q1 2023 and held it in 1 quarter.
  • Ikarian Capital's Rocket Pharmaceuticals Warrant position peaked at $60K in Q1 2023.
  • 16 funds tracked by Wall St. Rank held Rocket Pharmaceuticals Warrant as of Q2 2023.

Based on Ikarian Capital's 13F filing for Q2 2023, filed 14 Aug 2023.